Researchers at the University of Pittsburgh have developed a novel method for the selective attraction of CCR4-receptor engineered immune cells using CCL22 muteins. This innovative approach aims to enhance the efficacy of immune cell therapies by providing a highly specific targeting system, improving localization and reducing off-target effects. This technology has significant potential in transplantation, cancer therapy, and the treatment of autoimmune diseases.
Description
The invention involves the use of degradable, controlled-release microparticles (MP) to deliver CCL22 muteins, which selectively attract engineered immune cells expressing a paired CCR4 receptor. This ligand-receptor system allows for precise targeting of immune cell therapies, such as regulatory T cells (Tregs) and chimeric antigen receptor (CAR) T cells, to specific sites. The technology addresses the limitations of native CCL22-based therapies by avoiding the attraction of other endogenous immune cells that express the CCR4 receptor.
Applications
- Transplantation
- Cancer therapy
- Autoimmune disease treatment
- Immune cell therapy enhancement
Advantages
This technology provides a highly specific way to attract engineered immune cells to target sites, improving the localization and efficacy of immune cell therapies. It reduces off-target effects and enhances the therapeutic potential of treatments for transplantation, cancer, and autoimmune diseases. The use of CCL22 muteins paired with a designer CCR4 receptor ensures precise targeting and improved outcomes.
Invention Readiness
The concept has been defined, and initial evidence demonstrates the effectiveness of MP-delivery of human CCL22 in protecting human skin transplants on humanized mice. The technology is in the early stages of development, with ongoing research to further validate and optimize the approach.
IP Status
Patent pending
